[Prevention of recurrent myocardial infarcts by long-term aspirin therapy]

Area of Science:

• Cardiology
• Pharmacology
• Preventive Medicine

Background:

• Platelet aggregation plays a key role in myocardial infarction (MI) pathogenesis.
• Inhibition of platelet aggregation is a therapeutic target for secondary prevention of cardiovascular events.
• Aspirin is a widely used antiplatelet agent, but optimal dosing for long-term secondary prevention requires further elucidation.

Purpose of the Study:

• To evaluate the efficacy of daily 500 mg aspirin in preventing recurrent myocardial infarction and mortality in post-MI patients.
• To assess the duration of antiplatelet effect with daily aspirin administration.
• To compare cardiovascular outcomes in aspirin-treated patients versus a control group.

Main Methods:

• A randomized controlled trial comparing 570 patients treated with 500 mg aspirin daily for one year post-MI against 844 untreated controls.
• Monitoring of platelet aggregation inhibition.
• Assessment of incidence of recurrent MI, coronary mortality, sudden death, and total mortality.

Main Results:

• Daily 500 mg aspirin demonstrated lasting inhibition of platelet aggregation for one year.
• The aspirin-treated group showed a significant reduction in recurrent MI (13.1% to 8.9%).
• Coronary mortality (7.2% to 4.7%), sudden death rate (3.2% to 1.9%), and total mortality (9.3% to 6.6%) were also significantly decreased in the aspirin group.

Conclusions:

• Daily 500 mg aspirin is effective in providing long-term inhibition of platelet aggregation.
• This aspirin regimen significantly improves outcomes for patients following myocardial infarction.
• Aspirin therapy at this dose represents a valuable strategy for secondary prevention of cardiovascular events.